In the literature, clinical reports have shown that increased levels of serum PTH was frequently found in advanced prostate cancers [reviewed in ref. [5]], since the first description of possible secondary hyperparathyroidism (SHPT) as an accompanied syndrome with late-stage prostate cancer patients more than 46 years ago [6]. The gene discussed is PTH; the disease is secondary hyperparathyroidism.